GIP/GLP-1 & amylin agonists × body weight & composition

Observational studyJAMA internal medicine2024

Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.

Patricia J Rodriguez et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 5,140 people · 2024

Not counted

Raised body weight & composition

+76%+68% to +84%

Bigger than 8 in 10 on the map

As reported

HR 1.76, 95% CI 1.68–1.84

Not counted

Raised body weight & composition

2.5×2.4× to 2.7×

Bigger than 9 in 10 on the map

As reported

HR 2.54, 95% CI 2.37–2.73

Not counted

Raised body weight & composition

3.2×2.9× to 3.6×

Bigger than 9 in 10 on the map

As reported

HR 3.24, 95% CI 2.91–3.61

Not counted

Lowered body weight & composition

−2.40percentage points−2.50 to −2.20

As reported

difference −2.4 %, 95% CI −2.50 to −2.20

+2 more in the walkthrough ↓

Six numbers in the abstract

the abstract, start to end

weight loss (≥5%; hazard ratio [HR], 1.76, 95% CI, 1.68, 1.84; ≥10%; HR, 2.54; 95% CI, 2.37, 2.73; and ≥15%; HR, 3.24; 95% CI, 2.91, 3.61).

tirzepatide at 3 months (difference, -2.4%; 95% CI -2.5% to -2.2%), 6 months (difference, -4.3%; 95% CI, -4.7% to -4.0%), and 12 months (difference, -6.9%; 95% CI, -7.9% to -5.8%).

← favours treatmentfavours comparator →
could be chance
Body weight & composition
HR 1.761.68–1.84
Body weight & composition
HR 2.542.37–2.73
Body weight & composition
HR 3.242.91–3.61
Body weight & composition
−2.4−2.50 to −2.20
Body weight & composition
−4.3−4.70 to −4.00
Body weight & composition
−6.9−7.90 to −5.80
GIP/GLP-1 & amylin agonistsBody weight & composition
1 / 3

143 papers cite itlatest 60 shown

2024
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 38976257